Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy

被引：0
|
作者：
Ramdial, J. [1 ]
Chan, K. H. [1 ]
Sanchez Petitto, G. [1 ]
Valdez, B. [1 ]
Andersson, B. S. [1 ]
Nieto, Y. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; DAILY IV-BUSULFAN; VENOOCCLUSIVE DISEASE; FLUDARABINE; CYCLOPHOSPHAMIDE; REGIMEN; GEMCITABINE; MELPHALAN; TOXICITY;
D O I：
10.1038/s41409-023-01964-y
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：635 / 638
页数：4
相关论文
共 50 条
  • [1] Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
    Kebriaei, Partbw
    Anasetti, Claudio
    Zhang, Mei-Jie
    Wang, Hai-Lin
    Aldoss, Ibrahim
    de Lima, Marcos
    Khoury, H. Jean
    Sandmaier, Brenda M.
    Horowitz, Mary M.
    Artz, Andrew
    Bejanyan, Nelli
    Ciurea, Stefan
    Lazarus, Hillard M.
    Gale, Robert Peter
    Litzow, Mark
    Bredeson, Christopher
    Seftel, Matthew D.
    Pulsipher, Michael A.
    Boelens, Jaap-Jan
    Alvarnas, Joseph
    Champlin, Richard
    Forman, Stephen
    Pullarkat, Vinod
    Weisdorf, Daniel
    Marks, David L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (04) : 726 - 733
  • [2] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [3] Long-Term Outcomes after Treatment with Clofarabine Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome
    Alatrash, Gheath
    Thall, Peter F.
    Valdez, Benigno C.
    Fox, Patricia S.
    Ning, Jing
    Garber, Haven R.
    Janbey, Selma
    Worth, Laura L.
    Popat, Uday
    Hosing, Chitra
    Alousi, Amin M.
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Jones, Roy B.
    de Lima, Marcos
    Rondon, Gabriela
    Chen, Julianne
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1792 - 1800
  • [4] Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma
    Barta, Stefan K.
    Jain, Rishi
    Mazumder, Amithaba
    Carter, Jason
    Almanzar, Lawrence
    Browne, Roy
    Shahnaz, Samira
    Elkind, Richard
    Kaminetzky, David
    Battini, Ramakrishna
    Derman, Olga
    Kornblum, Noah
    Verma, Amit
    Braunschweig, Ira
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10) : 650 - 657
  • [5] Ovarian failure common with high-dose busulfan
    Reactions Weekly, 1999, 737 (1) : 6 - 6
  • [6] Sinusoidal obstruction syndrome;/veno-occlusive disease after high-dose intravenous busulfan;/melphalan conditioning therapy in high-risk Ewing Sarcoma
    Abate, Massimo Eraldo
    Paioli, Anna
    Cammelli, Sivlia
    Cesari, Marilena
    Longhi, Alessandra
    Palmerini, Emanuela
    Ferrari, Stefano
    Carretta, Elisa
    Picci, Piero
    Piscaglia, Fabio
    BONE MARROW TRANSPLANTATION, 2018, 53 (05) : 591 - 599
  • [7] High-dose busulfan-containing chemotherapy can cause IPS
    Reactions Weekly, 2001, 857 (1) : 5 - 5
  • [8] Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioning
    Protzenko, Dorian
    Bouchacourt, Benjamin
    Carriat, Laure
    Maroselli, Paul
    Boeri, Clara
    Devillier, Raynier
    Ciccolini, Joseph
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, : 1171 - 1181
  • [9] Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma
    Hänel, M
    Kröger, N
    Sonnenberg, S
    Bornhäuser, M
    Krüger, W
    Kroschinsky, F
    Hänel, A
    Metzner, B
    Birkmann, J
    Schmid, B
    Hoffknecht, MM
    Fiedler, F
    Ehninger, G
    Zander, AR
    ANNALS OF HEMATOLOGY, 2002, 81 (02) : 96 - 102
  • [10] Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant
    Puckrin, Robert
    Chua, Neil
    Shafey, Mona
    Stewart, Douglas A.
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2444 - 2452
12345